Does the media favor ONT or OXB?

In the previous week, Oxford Nanopore Technologies had 3 more articles in the media than Oxford Biomedica. MarketBeat recorded 4 mentions for Oxford Nanopore Technologies and 1 mentions for Oxford Biomedica. Oxford Nanopore Technologies' average media sentiment score of 1.09 beat Oxford Biomedica's score of 0.75 indicating that Oxford Nanopore Technologies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oxford Nanopore Technologies 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Oxford Biomedica 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend OXB or SLN?

Oxford Biomedica currently has a consensus target price of GBX 580.85, indicating a potential upside of 24.11%. Given Oxford Biomedica's stronger consensus rating and higher possible upside, equities research analysts plainly believe Oxford Biomedica is more favorable than Silence Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Oxford Biomedica 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80 Silence Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Does the media prefer OXB or AVCT?

In the previous week, Avacta Group had 1 more articles in the media than Oxford Biomedica. MarketBeat recorded 2 mentions for Avacta Group and 1 mentions for Oxford Biomedica. Oxford Biomedica's average media sentiment score of 0.75 beat Avacta Group's score of 0.00 indicating that Oxford Biomedica is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oxford Biomedica 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Avacta Group 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer HZD or OXB?

Oxford Biomedica has a consensus target price of GBX 580.85, indicating a potential upside of 24.11%. Given Oxford Biomedica's stronger consensus rating and higher probable upside, analysts clearly believe Oxford Biomedica is more favorable than Horizon Discovery Group plc (HZD.L). Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Horizon Discovery Group plc (HZD.L) 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Oxford Biomedica 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80

Does the media refer more to OXB or PRTC?

In the previous week, Oxford Biomedica and Oxford Biomedica both had 1 articles in the media. Oxford Biomedica's average media sentiment score of 0.75 beat PureTech Health's score of -1.32 indicating that Oxford Biomedica is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oxford Biomedica 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive PureTech Health 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Negative

Oxford Biomedica (OXB) Competitors

GBX 457.01 -7.99 (-1.72%)

As of 06:29 AM Eastern

Compare

OXB vs. ONT, SLN, AVCT, HZD, and PRTC

Should you buy Oxford Biomedica stock or one of its competitors? Oxford Biomedica's main competitors and comparable companies include Oxford Nanopore Technologies (ONT), Silence Therapeutics (SLN), Avacta Group (AVCT), Horizon Discovery Group plc (HZD.L) (HZD), and PureTech Health (PRTC). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Oxford Biomedica compare to Oxford Nanopore Technologies?

Oxford Nanopore Technologies (LON:ONT) and Oxford Biomedica (LON:OXB) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, analyst recommendations, earnings, profitability, media sentiment and dividends.

Oxford Biomedica has a net margin of -17.85% compared to Oxford Nanopore Technologies' net margin of -54.66%. Oxford Nanopore Technologies' return on equity of -35.45% beat Oxford Biomedica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oxford Nanopore Technologies	-54.66%	-35.45%	-14.42%
Oxford Biomedica	-17.85%	-48.56%	-12.67%

18.9% of Oxford Nanopore Technologies shares are held by institutional investors. Comparatively, 32.4% of Oxford Biomedica shares are held by institutional investors. 2.5% of Oxford Nanopore Technologies shares are held by insiders. Comparatively, 43.3% of Oxford Biomedica shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Oxford Biomedica has lower revenue, but higher earnings than Oxford Nanopore Technologies. Oxford Biomedica is trading at a lower price-to-earnings ratio than Oxford Nanopore Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oxford Nanopore Technologies	£235M	7.33	-£175.21M	-£12.50	N/A
Oxford Biomedica	£168.74M	3.36	-£143.51M	-£26.92	N/A

In the previous week, Oxford Nanopore Technologies had 3 more articles in the media than Oxford Biomedica. MarketBeat recorded 4 mentions for Oxford Nanopore Technologies and 1 mentions for Oxford Biomedica. Oxford Nanopore Technologies' average media sentiment score of 1.09 beat Oxford Biomedica's score of 0.75 indicating that Oxford Nanopore Technologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oxford Nanopore Technologies	1 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Oxford Biomedica	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Oxford Nanopore Technologies presently has a consensus target price of GBX 198.60, suggesting a potential upside of 12.78%. Oxford Biomedica has a consensus target price of GBX 580.85, suggesting a potential upside of 24.11%. Given Oxford Biomedica's higher possible upside, analysts clearly believe Oxford Biomedica is more favorable than Oxford Nanopore Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oxford Nanopore Technologies	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83
Oxford Biomedica	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80

Oxford Nanopore Technologies has a beta of 0.964, meaning that its stock price is 4% less volatile than the broader market. Comparatively, Oxford Biomedica has a beta of 1.092, meaning that its stock price is 9% more volatile than the broader market.

Summary

Oxford Nanopore Technologies beats Oxford Biomedica on 9 of the 16 factors compared between the two stocks.

How does Oxford Biomedica compare to Silence Therapeutics?

Oxford Biomedica (LON:OXB) and Silence Therapeutics (LON:SLN) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, media sentiment, valuation, profitability, dividends and institutional ownership.

32.4% of Oxford Biomedica shares are held by institutional investors. 43.3% of Oxford Biomedica shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Silence Therapeutics has a net margin of 0.00% compared to Oxford Biomedica's net margin of -17.85%. Silence Therapeutics' return on equity of 0.00% beat Oxford Biomedica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oxford Biomedica	-17.85%	-48.56%	-12.67%
Silence Therapeutics	N/A	N/A	N/A

Oxford Biomedica currently has a consensus target price of GBX 580.85, indicating a potential upside of 24.11%. Given Oxford Biomedica's stronger consensus rating and higher possible upside, equities research analysts plainly believe Oxford Biomedica is more favorable than Silence Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oxford Biomedica	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80
Silence Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Oxford Biomedica had 1 more articles in the media than Silence Therapeutics. MarketBeat recorded 1 mentions for Oxford Biomedica and 0 mentions for Silence Therapeutics. Oxford Biomedica's average media sentiment score of 0.75 beat Silence Therapeutics' score of 0.00 indicating that Oxford Biomedica is being referred to more favorably in the media.

Company	Overall Sentiment
Oxford Biomedica	Positive
Silence Therapeutics	Neutral

Silence Therapeutics has lower revenue, but higher earnings than Oxford Biomedica. Oxford Biomedica is trading at a lower price-to-earnings ratio than Silence Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oxford Biomedica	£168.74M	3.36	-£143.51M	-£26.92	N/A
Silence Therapeutics	£11.35M	0.00	N/A	-£48.60	N/A

Summary

Oxford Biomedica beats Silence Therapeutics on 9 of the 13 factors compared between the two stocks.

How does Oxford Biomedica compare to Avacta Group?

Oxford Biomedica (LON:OXB) and Avacta Group (LON:AVCT) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, dividends, profitability, media sentiment, institutional ownership and valuation.

Oxford Biomedica presently has a consensus price target of GBX 580.85, indicating a potential upside of 24.11%. Avacta Group has a consensus price target of GBX 99, indicating a potential upside of 26.92%. Given Avacta Group's stronger consensus rating and higher probable upside, analysts clearly believe Avacta Group is more favorable than Oxford Biomedica.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oxford Biomedica	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80
Avacta Group	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Oxford Biomedica has a beta of 1.092, suggesting that its stock price is 9% more volatile than the broader market. Comparatively, Avacta Group has a beta of 1.12, suggesting that its stock price is 12% more volatile than the broader market.

Oxford Biomedica has a net margin of -17.85% compared to Avacta Group's net margin of -33,961.06%. Oxford Biomedica's return on equity of -48.56% beat Avacta Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oxford Biomedica	-17.85%	-48.56%	-12.67%
Avacta Group	-33,961.06%	-2,929.47%	-21.80%

In the previous week, Avacta Group had 1 more articles in the media than Oxford Biomedica. MarketBeat recorded 2 mentions for Avacta Group and 1 mentions for Oxford Biomedica. Oxford Biomedica's average media sentiment score of 0.75 beat Avacta Group's score of 0.00 indicating that Oxford Biomedica is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oxford Biomedica	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Avacta Group	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

32.4% of Oxford Biomedica shares are held by institutional investors. Comparatively, 3.1% of Avacta Group shares are held by institutional investors. 43.3% of Oxford Biomedica shares are held by company insiders. Comparatively, 47.7% of Avacta Group shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Avacta Group has lower revenue, but higher earnings than Oxford Biomedica. Oxford Biomedica is trading at a lower price-to-earnings ratio than Avacta Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oxford Biomedica	£168.74M	3.36	-£143.51M	-£26.92	N/A
Avacta Group	£113K	3,234.23	-£30.08M	-£9.66	N/A

Summary

Avacta Group beats Oxford Biomedica on 9 of the 16 factors compared between the two stocks.

How does Oxford Biomedica compare to Horizon Discovery Group plc (HZD.L)?

Horizon Discovery Group plc (HZD.L) (LON:HZD) and Oxford Biomedica (LON:OXB) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, media sentiment, profitability, valuation, risk and institutional ownership.

32.4% of Oxford Biomedica shares are owned by institutional investors. 43.3% of Oxford Biomedica shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Horizon Discovery Group plc (HZD.L) has higher earnings, but lower revenue than Oxford Biomedica. Oxford Biomedica is trading at a lower price-to-earnings ratio than Horizon Discovery Group plc (HZD.L), indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Horizon Discovery Group plc (HZD.L)	£54.63M	0.00	N/A	-£5.50	N/A
Oxford Biomedica	£168.74M	3.36	-£143.51M	-£26.92	N/A

Oxford Biomedica has a consensus target price of GBX 580.85, indicating a potential upside of 24.11%. Given Oxford Biomedica's stronger consensus rating and higher probable upside, analysts clearly believe Oxford Biomedica is more favorable than Horizon Discovery Group plc (HZD.L).

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Horizon Discovery Group plc (HZD.L)	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Oxford Biomedica	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80

Horizon Discovery Group plc (HZD.L) has a net margin of 0.00% compared to Oxford Biomedica's net margin of -17.85%. Horizon Discovery Group plc (HZD.L)'s return on equity of 0.00% beat Oxford Biomedica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Horizon Discovery Group plc (HZD.L)	N/A	N/A	N/A
Oxford Biomedica	-17.85%	-48.56%	-12.67%

In the previous week, Oxford Biomedica had 1 more articles in the media than Horizon Discovery Group plc (HZD.L). MarketBeat recorded 1 mentions for Oxford Biomedica and 0 mentions for Horizon Discovery Group plc (HZD.L). Oxford Biomedica's average media sentiment score of 0.75 beat Horizon Discovery Group plc (HZD.L)'s score of 0.00 indicating that Oxford Biomedica is being referred to more favorably in the news media.

Company	Overall Sentiment
Horizon Discovery Group plc (HZD.L)	Neutral
Oxford Biomedica	Positive

Summary

Oxford Biomedica beats Horizon Discovery Group plc (HZD.L) on 9 of the 13 factors compared between the two stocks.

How does Oxford Biomedica compare to PureTech Health?

Oxford Biomedica (LON:OXB) and PureTech Health (LON:PRTC) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, profitability, earnings, dividends, media sentiment, valuation, risk and analyst recommendations.

32.4% of Oxford Biomedica shares are owned by institutional investors. Comparatively, 30.7% of PureTech Health shares are owned by institutional investors. 43.3% of Oxford Biomedica shares are owned by company insiders. Comparatively, 13.4% of PureTech Health shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Oxford Biomedica has a net margin of -17.85% compared to PureTech Health's net margin of -2,355.32%. PureTech Health's return on equity of -31.98% beat Oxford Biomedica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oxford Biomedica	-17.85%	-48.56%	-12.67%
PureTech Health	-2,355.32%	-31.98%	-13.39%

In the previous week, Oxford Biomedica and Oxford Biomedica both had 1 articles in the media. Oxford Biomedica's average media sentiment score of 0.75 beat PureTech Health's score of -1.32 indicating that Oxford Biomedica is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oxford Biomedica	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
PureTech Health	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Negative

Oxford Biomedica has a beta of 1.092, suggesting that its stock price is 9% more volatile than the broader market. Comparatively, PureTech Health has a beta of 0.771, suggesting that its stock price is 23% less volatile than the broader market.

Oxford Biomedica presently has a consensus target price of GBX 580.85, indicating a potential upside of 24.11%. PureTech Health has a consensus target price of GBX 508, indicating a potential upside of 320.93%. Given PureTech Health's stronger consensus rating and higher possible upside, analysts plainly believe PureTech Health is more favorable than Oxford Biomedica.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oxford Biomedica	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80
PureTech Health	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

PureTech Health has lower revenue, but higher earnings than Oxford Biomedica. Oxford Biomedica is trading at a lower price-to-earnings ratio than PureTech Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oxford Biomedica	£168.74M	3.36	-£143.51M	-£26.92	N/A
PureTech Health	£4.66M	63.51	-£91.86M	-£46.00	N/A

Summary

Oxford Biomedica beats PureTech Health on 9 of the 15 factors compared between the two stocks.

Get Oxford Biomedica News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OXB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

OXB vs. The Competition

Export

Metric	Oxford Biomedica	Biotechnology Industry	Healthcare Sector	LON Exchange
Market Cap	£566.51M	£3.90B	£7.25B	£2.90B
Dividend Yield	4.57%	3.64%	2.53%	6.23%
P/E Ratio	-17.38	14.12	274.81	366.89
Price / Sales	3.36	1,416.99	696.06	90,241.88
Price / Cash	3.01	41.62	28.04	27.89
Price / Book	6.91	15.64	10.59	6.41
Net Income	-£143.51M	-£22.86M	£3.49B	£5.89B
7 Day Performance	1.52%	0.72%	0.78%	1.21%
1 Month Performance	-10.46%	-4.68%	-2.82%	0.17%
1 Year Performance	-25.71%	34.72%	16.67%	19.68%

Oxford Biomedica Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
OXB Oxford Biomedica	2.9103 of 5 stars	GBX 457.01 -1.7%	GBX 580.85 +27.1%	-21.5%	£553.20M	£168.74M	N/A	891
ONT Oxford Nanopore Technologies	2.8092 of 5 stars	GBX 152.82 -3.4%	GBX 198.60 +30.0%	+10.7%	£1.49B	£235M	N/A	1,281	Positive News
SLN Silence Therapeutics	N/A	N/A	N/A	N/A	£480.35M	£11.35M	N/A	100	High Trading Volume
AVCT Avacta Group	1.7688 of 5 stars	GBX 68.90 -3.0%	GBX 99 +43.7%	+49.5%	£322.83M	£113K	N/A	120
HZD Horizon Discovery Group plc (HZD.L)	N/A	N/A	N/A	N/A	£302.98M	£54.63M	N/A	416

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:OXB) was last updated on 9/22/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Oxford Biomedica (OXB) Competitors

OXB vs. ONT, SLN, AVCT, HZD, and PRTC

How does Oxford Biomedica compare to Oxford Nanopore Technologies?

Summary

How does Oxford Biomedica compare to Silence Therapeutics?

Summary

How does Oxford Biomedica compare to Avacta Group?

Summary

How does Oxford Biomedica compare to Horizon Discovery Group plc (HZD.L)?

Summary

How does Oxford Biomedica compare to PureTech Health?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OXB vs. The Competition

Oxford Biomedica Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Oxford Biomedica (OXB) Competitors

OXB vs. ONT, SLN, AVCT, HZD, and PRTC

How does Oxford Biomedica compare to Oxford Nanopore Technologies?

Is ONT or OXB more profitable?

Do insiders and institutionals hold more shares of ONT or OXB?

Which has higher earnings & valuation, ONT or OXB?

Does the media favor ONT or OXB?

Do analysts rate ONT or OXB?

Which has more volatility & risk, ONT or OXB?

Summary

How does Oxford Biomedica compare to Silence Therapeutics?

Do insiders & institutionals have more ownership in OXB or SLN?

Is OXB or SLN more profitable?

Do analysts recommend OXB or SLN?

Does the media refer more to OXB or SLN?

Which has better earnings and valuation, OXB or SLN?

Summary

How does Oxford Biomedica compare to Avacta Group?

Do analysts prefer OXB or AVCT?

Which has more risk and volatility, OXB or AVCT?

Is OXB or AVCT more profitable?

Does the media prefer OXB or AVCT?

Do institutionals and insiders have more ownership in OXB or AVCT?

Which has higher valuation and earnings, OXB or AVCT?

Summary

How does Oxford Biomedica compare to Horizon Discovery Group plc (HZD.L)?

Do insiders and institutionals have more ownership in HZD or OXB?

Which has better valuation and earnings, HZD or OXB?

Do analysts prefer HZD or OXB?

Is HZD or OXB more profitable?

Does the media prefer HZD or OXB?

Summary

How does Oxford Biomedica compare to PureTech Health?

Do institutionals and insiders believe in OXB or PRTC?

Is OXB or PRTC more profitable?

Does the media refer more to OXB or PRTC?

Which has more volatility & risk, OXB or PRTC?

Do analysts prefer OXB or PRTC?

Which has higher earnings & valuation, OXB or PRTC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OXB vs. The Competition

Oxford Biomedica Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools